Factor Information
Data ID 2810
Factor Neutrophil gelatinase-associated lipocalin levels (NGAL)
Description Neutrophil gelatinase-associated lipocalin levels were higher at the first extracorporeal membrane oxygenation day in patients who underwent continuous venovenous hemofiltration, 285 (range, 181-513) vs. 130 (range, 81-277) ng/mL, in patients who did not undergo continuous venovenous hemofiltration (p = .045).
Biomarker YES
Classification E2 (physiological factor - biochemical index)
Association
Application diagnosis and prognosis
Objective To evaluate diagnostic and prognostic significance of neutrophil gelatinase-associated lipocalin during extracorporeal membrane oxygenation in children with congenital heart disease.
p Value 0.045
Conclusion Neutrophil gelatinase-associated lipocalin levels were higher at the first extracorporeal membrane oxygenation day in patients who underwent continuous venovenous hemofiltration, 285 (range, 181-513) vs. 130 (range, 81-277) ng/mL, in patients who did not undergo continuous venovenous hemofiltration (p = .045).
Risk Factor unknown
CHD Type
ID 626
CHD Type isolated CHD
CHD Subtype AVC/TA/TOF/HLHS/MS/AC, VSD/UVH, HAA
Reference
PMID 21057360
Year 2012
Title Neutrophil gelatinase-associated lipocalin levels during extracorporeal membrane oxygenation in critically ill children with congenital heart disease: preliminary experience
Sample
Population infants, children
Source Database
Region Rome, Italy
Method Prospective observational study.
Race Europe
Disease History N/A
Treatment History N/A
Group Patients on CVVH (continuous venovenous hemofiltration) (Treatment) Patients Not on CVVH(continuous venovenous hemofiltration) (Control)
Number 3 7
Age 31 (7–5008) days 13 (9–3056) days
Gender (Male: Female) N/A N/A
Marker Level 285 (range, 181-513) ng/mL 130 (range, 81-277) ng/mL